Drug Trial Radar · NCT06444113
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Nov 25, 2024
Primary completion
Feb 20, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Conditions
- Multiple Sclerosis
Interventions
OfatunumabDrug
No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of ofatumumab in breast milk.Time frame: (pre-dose) on the day of second (or subsequent) maintenance dose, then 7, 14, 21, 28 days after the second (or subsequent) maintenance dose"
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
UCSF
San Francisco, California
UC Health Neuroscience Ctr
Aurora, Colorado
Northwestern Medicine Northwestern University
Winfield, Illinois
Brigham and Womens Hospital
Brookline, Massachusetts
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Foggia, FG, Italy
Novartis Investigative Site
Bialystok, Poland
Novartis Investigative Site
Kielce, Poland
Novartis Investigative Site
Cambridge, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Oxford, United Kingdom
Novartis Investigative Site
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.